Jacob Kimmel

In this enlightening conversation, Jacob Kimmel, Co-founder and President of NewLimit, shares his groundbreaking work in reversing aging through epigenetic reprogramming. He discusses why evolution hasn't optimized for longevity and the complexities of drug discovery. The chat delves into the role of transcription factors in rejuvenating cells and innovative gene delivery methods that could transform medical treatments. Kimmel also offers intriguing insights into CAR-T cell therapy and how biotech innovations may revolutionize healthcare.

Jacob Kimmel, co-founder and president of New Limit, shares insights into revolutionary biotech aimed at reprogramming cellular aging. He discusses their groundbreaking work with transcription factors, which can potentially restore youthful cell functions. Exciting advancements in epigenetic reprogramming are revealed, including successes in rejuvenating old liver cells. Kimmel emphasizes the collaboration between academia and industry driving progress in longevity science, and the challenges faced in gene manipulation as they seek to enhance human health and lifespan.

Join Jacob Kimmel, co-founder of New Limit, as he discusses revolutionary approaches to extending human lifespan through epigenetic reprogramming. Santi Ruiz from the Institute for Progress shares insights on the intersection of innovation policy and nonprofit challenges in tech. Kelvin Yu explores the dynamics of Silicon Valley's tech culture, while Jim Blum sheds light on advancements in shipbuilding. Fil Aronshtein navigates the complexities of AI and Hollywood, sparking a lively conversation about the future of both industries.